Patents by Inventor Daniel Spinks

Daniel Spinks has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • 1-arylsulfonyl-3-substituted indole and indoline derivatives useful in the treatment of central nervous system disorders
    Patent number: 7838518
    Abstract: The present invention relates to 1-arylsulfonyl-3 substituted indole or indoline derivatives having the general formula (I) (I) wherein the dotted line represents an optional bond; n is 0 or 1; m is 0-5 and Ar, R6-R11 are defined in the description. The invention further relates to pharmaceutical compositions comprising said derivatives, and to the use of these 1-arylsulfonyl-3-substituted indole or indoline derivatives in the treatment of central nervous disorders such as psychosis, schizophrenia, manic depressions, depressions, neurological disorders, cognitive enhancement, Parkinson's disease, amyotrophic lateral sclerosis, Alzheimer's disease and Huntington's disease.
    Type: Grant
    Filed: February 5, 2003
    Date of Patent: November 23, 2010
    Assignee: N.V. Organon
    Inventors: Daniel Spinks, Richard E. Armer, David J. Miller, Zoran Rankovic, Gayle Spinks, Jordi Mestres, David Robert Jaap
  • 1-arylsulfonyl-3-substituted indole and indoline derivatives useful in the treatment of central nervous system disorders
    Publication number: 20050154023
    Abstract: The present invention relates to 1-arylsulfonyl-3-substituted indole or indoline derivatives having the general formula I wherein the dotted line represents an optional bond; n is 0 or 1; m is 0-5 and Ar, R6-R11, are defined in the description. The invention further relates to pharmaceutical compositions comprising said derivatives, and to the use of these 1-arylsulfonyl-3-substituted indole or indoline derivatives in the treatment of central nervous disorders such as psychosis, schizophrenia, manic depressions, depressions, neurological disorders, cognitive enhancement, Parkinson's disease, amyotrophic lateral sclerosis, Alzheimer's disease and Huntington's disease.
    Type: Application
    Filed: February 5, 2003
    Publication date: July 14, 2005
    Inventors: Daniel Spinks, Richard Armer, David Miller, Zoran Rankovic, Gayle Spinks, Jordi Mestres, David Jaap
  • Phenylsulphonyl derivatives as 5-HT receptor ligands
    Patent number: 6777430
    Abstract: A class of phenylsulphonyl derivatives wherein the sulphonyl moiety is also attached to an N-arylalkyl-substituted azetidine, pyrrolidine or piperidine ring are selective antagonists of the human 5-HT2A receptor and are therefore useful as pharmaceutical agents, especially in the treatment and/or prevention of adverse conditions of the central nervous system, including schizophrenia and depression.
    Type: Grant
    Filed: April 1, 2003
    Date of Patent: August 17, 2004
    Assignee: Merck Sharp & Dohme Ltd.
    Inventors: Peter Blurton, Frank Burkamp, Susan Koon-Fung Cheng, Stephen Robert Fletcher, Angus Murray MacLeod, Daniel Spinks, Monique Bodil Van Niel
  • Phenylsulphonyl derivatives as 5-HT receptor ligands
    Publication number: 20030203889
    Abstract: A class of phenylsulphonyl derivatives wherein the sulphonyl moiety is also attached to an N-arylalkyl-substituted azetidine, pyrrolidine or piperidine ring are selective antagonists of the human 5-HT2A receptor and are therefore useful as pharmaceutical agents, especially in the treatment and/or prevention of adverse conditions of the central nervous system, including schizophrenia and depression.
    Type: Application
    Filed: April 1, 2003
    Publication date: October 30, 2003
    Applicant: Merck & Co., Inc.
    Inventors: Peter Blurton, Frank Burkamp, Susan Koon-Fung Cheng, Stephen Robert Fletcher, Angus Murray MacLeod, Daniel Spinks, Monique Bodil Van Niel
  • Phenylsulphonyl derivatives as 5-HT receptor ligands
    Patent number: 6559166
    Abstract: A class of phenylsulphonyl derivatives wherein the sulphonyl moiety is also attached to an N-arylalkyl-substituted azetidine, pyrrolidine or piperidine ring are selective antagonists of the human 5-HT2A receptor and are therefore useful as pharmaceutical agents, especially in the treatment and/or prevention of adverse conditions of the central nervous system, including schizophrenia and depression.
    Type: Grant
    Filed: September 27, 2001
    Date of Patent: May 6, 2003
    Assignee: Merck Sharp & Dohme Ltd.
    Inventors: Peter Blurton, Frank Burkamp, Susan Koon-Fung Cheng, Stephen Robert Fletcher, Angus Murray MacLeod, Daniel Spinks, Monique Bodil Van Niel